These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26653336)

  • 1. Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.
    Chen B; Roy SG; McMonigle RJ; Keebaugh A; McCracken AN; Selwan E; Fransson R; Fallegger D; Huwiler A; Kleinman MT; Edinger AL; Hanessian S
    ACS Chem Biol; 2016 Feb; 11(2):409-14. PubMed ID: 26653336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    McCracken AN; McMonigle RJ; Tessier J; Fransson R; Perryman MS; Chen B; Keebaugh A; Selwan E; Barr SA; Kim SM; Roy SG; Liu G; Fallegger D; Sernissi L; Brandt C; Moitessier N; Snider AJ; Clare S; Müschen M; Huwiler A; Kleinman MT; Hanessian S; Edinger AL
    Leukemia; 2017 Mar; 31(3):669-677. PubMed ID: 27573555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of new ligands for targeting the S1P1 receptor.
    Schilson SS; Keul P; Shaikh RS; Schäfers M; Levkau B; Haufe G
    Bioorg Med Chem; 2015 Mar; 23(5):1011-26. PubMed ID: 25656338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
    Zehra Okus F; Busra Azizoglu Z; Canatan H; Eken A
    Int Immunopharmacol; 2022 Jun; 107():108665. PubMed ID: 35255303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
    Kalhori V; Magnusson M; Asghar MY; Pulli I; Törnquist K
    Endocr Relat Cancer; 2016 May; 23(5):457-68. PubMed ID: 26935838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P(3) and phosphoinositide 3-kinase.
    Imeri F; Blanchard O; Jenni A; Schwalm S; Wünsche C; Zivkovic A; Stark H; Pfeilschifter J; Huwiler A
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1283-92. PubMed ID: 26267293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.
    Grenald SA; Doyle TM; Zhang H; Slosky LM; Chen Z; Largent-Milnes TM; Spiegel S; Vanderah TW; Salvemini D
    Pain; 2017 Sep; 158(9):1733-1742. PubMed ID: 28570482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of sphingosine 1-phosphate on functions of T cell - review].
    Huang WR; Wang LS; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A; Igarashi Y
    Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
    Shaikh RS; Keul P; Schäfers M; Levkau B; Haufe G
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5048-51. PubMed ID: 26592813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
    Clemens JJ; Davis MD; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia.
    Serdar M; Herz J; Kempe K; Lumpe K; Reinboth BS; Sizonenko SV; Hou X; Herrmann R; Hadamitzky M; Heumann R; Hansen W; Sifringer M; van de Looij Y; Felderhoff-Müser U; Bendix I
    Brain Behav Immun; 2016 Feb; 52():106-119. PubMed ID: 26456693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sphingosine 1-Phosphate Analogue FTY720 Alleviates Seizure-induced Overexpression of P-Glycoprotein in Rat Hippocampus.
    Gao F; Gao Y; Meng F; Yang C; Fu J; Li Y
    Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):14-20. PubMed ID: 29380527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
    Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
    Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.
    Katsuta E; Yan L; Nagahashi M; Raza A; Sturgill JL; Lyon DE; Rashid OM; Hait NC; Takabe K
    J Surg Res; 2017 Nov; 219():202-213. PubMed ID: 29078883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.
    Keller CD; Rivera Gil P; Tölle M; van der Giet M; Chun J; Radeke HH; Schäfer-Korting M; Kleuser B
    Am J Pathol; 2007 Jan; 170(1):281-92. PubMed ID: 17200201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
    Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of FTY720 (Fingolimod) in cancer treatment.
    White C; Alshaker H; Cooper C; Winkler M; Pchejetski D
    Oncotarget; 2016 Apr; 7(17):23106-27. PubMed ID: 27036015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.
    Huwiler A; Zangemeister-Wittke U
    Pharmacol Ther; 2018 May; 185():34-49. PubMed ID: 29127024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.